Grifols, S.A. – NASDAQ:GRFS
Grifols, S.A. stock price today
$10.19
+2.53
+33.2%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in 18 minutes
Grifols, S.A. stock price monthly change
-7.38%
month
Grifols, S.A. stock price quarterly change
-7.38%
quarter
Grifols, S.A. stock price yearly change
-25.58%
year
Grifols, S.A. key metrics
Market Cap | 5.88B |
Enterprise value | 14.15B |
P/E | 20.78 |
EV/Sales | 2.54 |
EV/EBITDA | 10.58 |
Price/Sales | 0.78 |
Price/Book | 0.68 |
PEG ratio | 1.57 |
EPS | 0.28 |
Revenue | 6.65B |
EBITDA | 1.18B |
Income | 196.99M |
Revenue Q/Q | 5.38% |
Revenue Y/Y | 4.99% |
Profit margin | 11.29% |
Oper. margin | 19.62% |
Gross margin | 42.74% |
EBIT margin | 19.62% |
EBITDA margin | 17.77% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeGrifols, S.A. stock price history
Grifols, S.A. stock forecast
Grifols, S.A. financial statements
| Jun 2023 | 1.66B | 60.03M | 3.61% |
|---|---|---|---|
| Sep 2023 | 1.59B | 59.54M | 3.73% |
| Dec 2023 | 1.76B | 55.99M | 3.16% |
| Mar 2024 | 1.62B | 21.41M | 1.32% |
| Sep 2025 | 1.59B | 134.56M | 8.45% |
|---|---|---|---|
| Dec 2025 | 1.45B | 138.50M | 9.51% |
| Dec 2025 | 1.45B | 138.59M | 9.52% |
| Mar 2026 | 2.99B | 0 |
Analysts Price target
Financials & Ratios estimates
0%
Yield TTM
| Payout ratio | 0% |
|---|
| 2019 | 1.68% |
|---|---|
| 2020 | 1.1% |
| 2021 | 3.86% |
| 2022 | 0.01% |
| 2023 |
| Jun 2023 | 21432744000 | 13.20B | 61.63% |
|---|---|---|---|
| Sep 2023 | 22064498000 | 13.49B | 61.17% |
| Dec 2023 | 21454670000 | 13.46B | 62.78% |
| Mar 2024 | 21953010000 | 13.83B | 63% |
| Jun 2023 | -42.27M | -49.83M | 189.93M |
|---|---|---|---|
| Sep 2023 | 155.63M | -122.88M | -79.37M |
| Dec 2023 | 156.38M | -141.88M | 46.47M |
| Mar 2024 | -164.92M | -87.95M | 165.45M |
Grifols, S.A. alternative data
What is job openings count?
| Aug 2023 | 552 |
|---|---|
| Sep 2023 | 906 |
| Oct 2023 | 798 |
| Nov 2023 | 899 |
| Dec 2023 | 781 |
| Jan 2024 | 626 |
| Feb 2024 | 588 |
| Apr 2024 | 571 |
| May 2024 | 584 |
| Jun 2024 | 484 |
| Jul 2024 | 587 |
| Aug 2023 | 26,326 |
|---|---|
| Sep 2023 | 23,631 |
| Oct 2023 | 23,631 |
| Nov 2023 | 23,631 |
| Dec 2023 | 24,000 |
| Jan 2024 | 24,000 |
| Feb 2024 | 24,000 |
| Mar 2024 | 23,744 |
| Apr 2024 | 23,744 |
| May 2024 | 23,744 |
| Jun 2024 | 23,000 |
| Jul 2024 | 23,000 |
Grifols, S.A. other data
6.51%
-8.84%
of GRFS is owned by hedge funds
77
-47
44.20M
-60.40M
shares is hold by hedge funds
| Quarter | Transcript |
|---|---|
| Q1 2024 14 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 29 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 2 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 27 Jul 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Raimon Grifols Roura (1964) Co-Chief Executive Officer & Executive Director | $1,320,000 |
Mr. VĂctor GrĂfols Deu (1977) Co-Chief Executive Officer & Executive Director | $1,320,000 |
Showcasing Seeking Alpha's May 2024 New Analysts
Grifols: Wait And See For Now
Grifols: I've Read The Short-Seller Report, And I Mostly Disagree
Doubling Down On Gain Therapeutics
Grifols Is Building Momentum
Grifols: A Promising Buy Opportunity
Grifols: Upside After A Smashing Q1 2023 - I Say 'Buy'
CSL Limited: Well Placed To Execute Growth Plans And Generate Shareholder Value
Grifols: A Favorite For Some, Speculative Buy For Me
-
What's the price of Grifols, S.A. stock today?
One share of Grifols, S.A. stock can currently be purchased for approximately $10.19.
-
When is Grifols, S.A.'s next earnings date?
Unfortunately, Grifols, S.A.'s (GRFS) next earnings date is currently unknown.
-
Does Grifols, S.A. pay dividends?
No, Grifols, S.A. does not pay dividends.
-
How much money does Grifols, S.A. make?
Grifols, S.A. has a market capitalization of 5.88B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 8.71% to 6.59B US dollars.
-
What is Grifols, S.A.'s stock symbol?
Grifols, S.A. is traded on the NASDAQ under the ticker symbol "GRFS".
-
What is Grifols, S.A.'s primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - General industry.
-
How do i buy shares of Grifols, S.A.?
Shares of Grifols, S.A. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Grifols, S.A.'s key executives?
Grifols, S.A.'s management team includes the following people:
- Mr. Raimon Grifols Roura Co-Chief Executive Officer & Executive Director(age: 61, pay: $1,320,000)
- Mr. VĂctor GrĂfols Deu Co-Chief Executive Officer & Executive Director(age: 48, pay: $1,320,000)
-
How many employees does Grifols, S.A. have?
As Jul 2024, Grifols, S.A. employs 23,000 workers, which is 3% less then previous quarter.
-
When Grifols, S.A. went public?
Grifols, S.A. is publicly traded company for more then 14 years since IPO on 2 Jun 2011.
-
What is Grifols, S.A.'s official website?
The official website for Grifols, S.A. is grifols.com.
-
How can i contact Grifols, S.A.?
Grifols, S.A. can be reached via phone at +34 935 71 02 21.
Grifols, S.A. company profile:
Grifols, S.A.
grifols.comExchange:
NASDAQ
Full time employees:
23,000
Industry:
Drug Manufacturers - General
Sector:
Healthcare
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuum–from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring–to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
Avinguda de la Generalitat, 152
Barcelona, 08174
Barcelona, 08174
CIK: 0001438569
ISIN: US3984384087
CUSIP: 398438408
